 LEXINGTON, Mass., April 20, 2021 GLOBE NEWSWIRE -- Kaleido Biosciences, Inc. Nasdaq: KLDO, a clinical-stage healthcare company with a small molecule driven approach to targeting the microbiome to treat disease and improve human health, today announced a research collaboration with researcher Robert Jenq, M.D. Professor of Genomic Medicine, at The University of Texas MD Anderson Cancer Center, to explore the potential of Kaleidos novel Microbiome Metabolic Therapies MMTTM in preventing febrile neutropeniaa serious complication associated with hematopoietic stem cell transplantations HSCT. 